US Winston Online Club

The transfer into clinical development of a patient-specific vaccine represents a milestone for Bayer Innovation GmbH. Following approval of the Phase I study by the FDA (Food & Drug Administration) in the United States, the vaccine is now being tested in human subjects. This is the first time that proteins obtained from tobacco plants using magnICON® technology undergo clinical testing. The patient-specific vaccines produced in the pilot plant operated by the Bayer-subsidiary Icon Genetics in Halle, Germany, are intended for the treatment of non-Hodgkin’s lymphoma (NHL), a type of cancer affecting lymphocytes. The objective of the therapy is to activate the patient’s immune system, enabling the malignant cells to be targeted and destroyed by the body’s own defense system. ... read more >>